Suppr超能文献

距下关节骨关节炎关节腔内注射透明质酸:一项初步研究。

Intra-articular injections of hyaluronic acid in osteoarthritis of the subtalar joint: a pilot study.

作者信息

Mei-Dan Omer, Carmont Michael, Laver Lior, Mann Gideon, Maffulli Nicola, Nyska Meir

机构信息

Department of Orthopedic Surgery, Meir University Hospital, Kfar-Saba, Israel.

出版信息

J Foot Ankle Surg. 2013 Mar-Apr;52(2):172-6. doi: 10.1053/j.jfas.2012.12.008. Epub 2013 Jan 17.

Abstract

We evaluated the efficacy of intra-articular viscosupplementation with sodium hyaluronate in the management of osteoarthritis of the subtalar joint. A total of 22 patients, aged 22 to 72 years (mean 53), with symptomatic subtalar joint osteoarthritis of 1 to 20 years' duration (mean 4.2) and a severity of Kellgren-Lawrence grade II to IV and Paley and Hall grade 1 to 3, were entered into the present study. Intra-articular injections of 10 mg sodium hyaluronate (Euflexxa) were administered weekly to the subtalar joint for 3 weeks. Clinical evaluations and objective scoring using the American Orthopaedic Foot and Ankle Society Ankle Hindfoot score, visual analog scale, maximum walking distance, pain frequency, and subjective global function were performed at baseline and 4, 12, and 28 weeks after treatment. Significant improvement occurred in the American Orthopaedic Foot and Ankle Society Ankle Hindfoot scores (baseline score 54.5, week 28 score 73.7; p < .01) and visual analog scale assessment (baseline pain, stiffness, and function score 5.4, 5.8, and 6.9; week 28 pain, stiffness, and function score 2.8, 3.1, and 3.8, respectively; p < .01). Global assessment showed improvement in 18 of 20 patients completing the study (p < .01). The tolerated walking distance significantly improved from 770 ± 886 m to 2,075 ± 1,500 m (p < .001). Improvement lasted for more than 6 months. Intra-articular injection of sodium hyaluronate should be considered in the conservative management of subtalar osteoarthritis.

摘要

我们评估了关节腔内注射透明质酸钠补充疗法在距下关节骨关节炎治疗中的疗效。本研究共纳入22例患者,年龄在22至72岁之间(平均53岁),有症状的距下关节骨关节炎病程为1至20年(平均4.2年),Kellgren-Lawrence分级为II至IV级,Paley和Hall分级为1至3级。每周向距下关节腔内注射10mg透明质酸钠(优维显),共注射3周。在基线以及治疗后4周、12周和28周进行临床评估,并使用美国矫形足踝协会踝后足评分、视觉模拟量表、最大行走距离、疼痛频率和主观整体功能进行客观评分。美国矫形足踝协会踝后足评分有显著改善(基线评分为54.5,第28周评分为73.7;p <.01),视觉模拟量表评估也有改善(基线时疼痛、僵硬和功能评分分别为5.4、5.8和6.9;第28周时疼痛、僵硬和功能评分分别为2.8、3.1和3.8;p <.01)。整体评估显示,完成研究的20例患者中有18例病情改善(p <.01)。耐受行走距离从770±886米显著提高到2075±1500米(p <.001)。改善持续超过6个月。在距下关节骨关节炎的保守治疗中,应考虑关节腔内注射透明质酸钠。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验